| We represent the needs and concerns of our target population in joint discussions with regulatory authorities and industry stakeholders across a range of networks. | 妇科
> 妇科：其他 | 监管合作伙伴关系
> 与监管机构合作 | 100,000 | National | Sometimes | 115028466428 |
| We periodically prepare statements for submission as supporting documentation to drug reimbursement applications. | 未指定
> 未指定 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 10,000 | National | Sometimes | 114998339214 |
| We periodically prepare submissions to accompany medicine reimbursement applications. | 未指定
> 未指定 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 10,000 | National | Sometimes | 114998339214 |
| We provide formal submissions, and I have personally participated in consultation processes — for example, as part of the working group tasked with developing the pharmaceutical reimbursement system. | 骨骼
> 骨关节炎 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 10,000 | National | Regularly | 114998343058 |
| Patient organisation submissions to the authorities responsible for reimbursement decisions. | 癌症
> 癌症：乳腺癌 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 10,000 | National | Sometimes | 115043746918 |
| We are a patient organisation representing individuals living with osteoporosis, and we advocate for the patient perspective in all our interactions with regulatory authorities. | 骨骼
> 骨质疏松症 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 100,000 | National | Regularly | 114998337721 |
| We represent the needs and concerns of our target population in joint discussions with regulatory authorities and industry stakeholders across a range of networks. | 妇科
> 妇科：其他 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 100,000 | National | Sometimes | 115028466428 |
| We submit statements to regulatory channels from a patient perspective. | 癌症
> 癌症：大多数类型 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | Do not know | National | Regularly | 115040330840 |
| Occasional position statements and opinions, often issued jointly with another organisation or under the auspices of an umbrella body. | 风湿性
> 狼疮 | 监管合作伙伴关系
> 与其他医疗保健倡导者 | 5,000 | National | Rarely | 115002845827 |
| Where there is a need to advocate or submit a formal statement, for example, we do so. | 总体健康
> 性健康：其他 | 影响政策和立法
> 影响医疗保健政策和立法 | 10,000 | National | Rarely | 115000148067 |
| We provide formal submissions, and I have personally participated in consultation processes — for example, as part of the working group tasked with developing the pharmaceutical reimbursement system. | 骨骼
> 骨关节炎 | 影响政策和立法
> 参与公众听证会和咨询 | 10,000 | National | Regularly | 114998343058 |
| We submit consultation responses. | 骨骼
> 骨关节炎 | 影响政策和立法
> 参与公众听证会和咨询 | 10,000 | National | Regularly | 114998343058 |
| Engagement with the city and the wellbeing services county to extend free pharmaceutical treatment to type 2 diabetes medicines. | 内分泌
> 糖尿病（1型和2型） | 定价与可负担性倡导
> 倡导公平的药品定价 | 1,000 | Regional | Sometimes | 115006989892 |
| Medicine pricing, Kela [Kansaneläkelaitos – Social Insurance Institution of Finland] reimbursement procedures, pharmacy services, and out-of-pocket medicine costs. | 残疾
> 残疾：大多数类型 | 定价与可负担性倡导
> 倡导公平的药品定价 | 1,000 | National | Regularly | 115007749998 |
| The price of obesity medicines. | 患者权益倡导
> 健康活动人士 | 定价与可负担性倡导
> 倡导公平的药品定价 | 1,000 | National | Sometimes | 115060416441 |
| For example, the Kela [Kansaneläkelaitos – Social Insurance Institution of Finland] medicine credit pilot [a Finnish policy experiment designed to help low-income patients afford high-cost prescription medicines when they face a large out-of-pocket payment all at once], which commenced on 27 October and will run for three years. | 皮肤
> 银屑病 | 定价与可负担性倡导
> 解决低收入和弱势群体面临的费用障碍 | 10,000 | National | Regularly | 115000293575 |
| Medicine pricing, Kela [Kansaneläkelaitos – Social Insurance Institution of Finland] reimbursement procedures, pharmacy services, and out-of-pocket medicine costs. | 残疾
> 残疾：大多数类型 | 定价与可负担性倡导
> 解决低收入和弱势群体面临的费用障碍 | 1,000 | National | Regularly | 115007749998 |
| Engagement with the city and the wellbeing services county to extend free pharmaceutical treatment to type 2 diabetes medicines. | 内分泌
> 糖尿病（1型和2型） | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 1,000 | Regional | Sometimes | 115006989892 |
| Patient organisation submissions to promote medicine reimbursement and access. | 神经肌肉
> 肌营养不良症 | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 5,000 | National | Regularly | 115007479426 |
| Medicine pricing, Kela [Kansaneläkelaitos – Social Insurance Institution of Finland] reimbursement procedures, pharmacy services, and out-of-pocket medicine costs. | 残疾
> 残疾：大多数类型 | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 1,000 | National | Regularly | 115007749998 |
| For example, the Kela [Kansaneläkelaitos – Social Insurance Institution of Finland] medicine credit pilot [a Finnish policy experiment designed to help low-income patients afford high-cost prescription medicines when they face a large out-of-pocket payment all at once], which commenced on 27 October and will run for three years. | 皮肤
> 银屑病 | 改善访问路径
> 促进公平获取药品/医疗保健 | 10,000 | National | Regularly | 115000293575 |
| Engagement with the city and the wellbeing services county to extend free pharmaceutical treatment to type 2 diabetes medicines. | 内分泌
> 糖尿病（1型和2型） | 改善访问路径
> 促进公平获取药品/医疗保健 | 1,000 | Regional | Sometimes | 115006989892 |
| Patient organisation submissions to promote medicine reimbursement and access. | 神经肌肉
> 肌营养不良症 | 改善访问路径
> 促进公平获取药品/医疗保健 | 5,000 | National | Regularly | 115007479426 |
| We are a patient organisation representing individuals living with osteoporosis, and we advocate for the patient perspective in all our interactions with regulatory authorities. | 骨骼
> 骨质疏松症 | 循证患者意见
> 利用患者洞察来指导决策 | 100,000 | National | Regularly | 114998337721 |
| We submit statements to regulatory channels from a patient perspective. | 癌症
> 癌症：大多数类型 | 循证患者意见
> 利用患者洞察来指导决策 | Do not know | National | Regularly | 115040330840 |
| ... We are represented on Fimea's [Lääkealan turvallisuus- ja kehittämiskeskus – Finnish Medicines Agency] patient advisory board. | 未指定
> 未指定 | 机构治理
> 确保在政府咨询机构中的代表性 | 10,000 | National | Sometimes | 114998339214 |
互动
行动与倡导
8 提及
